<DOC>
	<DOCNO>NCT02984566</DOCNO>
	<brief_summary>Primary secondary liver cancer patient receive liver SABR without KIM intervention .</brief_summary>
	<brief_title>Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring ( KIM )</brief_title>
	<detailed_description>This single arm , phase II , two stage study design evaluate cancer target accuracy , treatment outcome treatment efficiency 46 patient eligible SABR either primary secondary liver malignancy incorporation KIM .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>ECOG performance status 01 Life expectancy &gt; 6 month Number lesion : ≤ 3 Lesion size : &lt; 10 cm single lesion ( 10 cm cumulative diameter multiple lesion ) ChildPugh A B7 within 6 week prior study entry Unsuitable RFA resection transplant Distance GTV luminal structure ( i.e. , oesophagus , stomach , duodenum , small large bowel ) ≥ 10mm All blood work obtain within 6 week prior study entry adequate organ function May previous surgery , RFA ethanol injection Patient must discuss multidisciplinary tumour board consensus opinion SBRT HCC/cholangiocarcinoma evidence metastatic disease include nodal distant metastasis Metastatic disease complete liver disease response firstline chemotherapy ( i.e . target SBRT ) Previous radiation liver ( include SIRTEX ) Untreated HIV active hepatitis B/C On systemic antineoplastic drug therapy within 7 day inclusion Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary liver cancer</keyword>
	<keyword>Secondary liver cancer</keyword>
	<keyword>Kilovoltage Intrafraction Monitoring</keyword>
	<keyword>Stereotactic Ablative Body Radiation</keyword>
</DOC>